Promoter holding
64.27%
SN
Sundyota Numandis Probioceuticals Private Limited - Due diligence report
A 360° intelligence report on Sundyotanumandis: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sundyotanumandis — 360° Intelligence Report
Generated from MCA filings & public records94/100
Trust Score
Low Risk
Sundyotanumandis is assessed as Low Risk with a Trust Score of 94/100. Sundyotanumandis is an active private limited indian non-government company incorporated in 2011, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 20 Aug 2026 from the latest processed filings. Sundyota Numandis Probioceuticals Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
94/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (BBB-).
Charges position: 3 open (121.28 cr) · 2 satisfied (9.83 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 3 | 48.0 cr |
| Idbi Bank Limited | 2 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 5 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BIMAL INDRAVADAN TRIVEDI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KETUL RAJENDRA SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DINESH KUMAR ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Sundyota Numandis Pharmaceuticals Private Limited
Subsidiaries
-
Group entities
-
Capital events
8 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Sundyota Numandis Pharmaceuticals Private Limited | Holding Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 121.28 cr already registered.
- Compliance record supports lending.
Investor view95/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
05 Jul 2021
Charge satisfied
Idbi Bank Limited
22 Dec 2020
Charge satisfied
Idbi Bank Limited
22 Feb 2019
Charge created
State Bank Of India - 52.50 cr
19 Feb 2019
Charge created
Idbi Bank Limited - 33.00 Lakh
12 Feb 2019
Securities allotted
311770 Equity Shares - 2.65 cr raised
25 Jan 2019
Charge created
State Bank Of India - 51.62 cr
Charge created
State Bank Of India - 17.16 cr
20 Mar 2018
Securities allotted
738724 Equity Shares - 4.36 cr raised
13 Jan 2018
Securities allotted
676531 Equity Shares - 3.99 cr raised
25 May 2015
Securities allotted
400000.00 Equity Shares - 40.00 Lakh raised
Charge created
Idbi Bank Limited - 9.50 cr
14 Mar 2015
Director ceased
MOHIT TAMHANKAR
28 Jan 2015
Securities allotted
62500.00 Equity Shares - 6.25 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
5 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB- from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 8 security allotment(s) - amounts available in the full report.
3 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Anthea Aromatics | U24100MH2008PTC179684 | Navi Mumbai, Maharashtra, India |
| Anthea | U24240MH1985PTC038118 | Navi Mumbai, Maharashtra, India |
| Kamsons | U24100MH1996PTC099064 | Mumbai, Maharashtra, India |
| Kamsons Polymers Limited | U24230MH2005PLC151012 | Mumbai, Maharashtra, India |
| Jay Organics Private Limited | U24299GJ2019PTC110748 | Ahmedabad, Gujarat, India |
| Kubochem | U24100MH1978PTC020754 | Mumbai, Maharashtra, India |
| Amal Limited | L24100MH1974PLC017594 | Mumbai, Maharashtra, India |
| Shelter Pharma | L24233GJ2007PLC051956 | Himmatnagar, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sundyotanumandis before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sundyotanumandis: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Sundyotanumandis - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 94/100, distress signals and MSME payment-delay disclosures - know whether Sundyotanumandis pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Sundyotanumandis - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sundyotanumandis an active company?
Sundyotanumandis has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Sundyotanumandis financially healthy?
Sundyotanumandis has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Sundyotanumandis?
Its overall Trust Score is 94/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sundyotanumandis?
The ultimate holding entity is Sundyota Numandis Pharmaceuticals Private Limited. 3 active director(s) are on record.
Does Sundyotanumandis have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Sundyotanumandis up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Sundyotanumandis?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
